Mucositis :: Palifermin – Kepivance – to treat mucositis with cancer treatments
The Food and Drug Administration (FDA) approved a new intravenous biologic product, palifermin (trade-name Kepivance) to help reduce the chance that certain cancer patients, those with blood cancers undergoing chemotherapy and radiation in preparation for bone marrow transplants, will develop mucositis. Palifermin also shortens the duration of the condition.